[{"data":1,"prerenderedAt":182},["ShallowReactive",2],{"drug-sitagliptin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":52,"contraindications":91,"warnings":92,"renal":93,"monitoring":94,"interactions":95,"review":96,"examples":99,"atc":105,"iran":107,"links":127,"populations":144,"usApproval":177},"sitagliptin",1,{"fa":7,"en":8},"سیتاگلیپتین","Sitagliptin","alimentary-metabolism",{"fa":11,"en":12},"مهارکننده DPP-4","DPP-4 inhibitor",[14],{"name":15,"market":16},"Januvia","US",[18,19,7,20],"januvia","جانویا","DPP4",[22,36,44],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-25","tablet","oral","25 mg tablet",{"amount":28,"unit":29,"perUnit":24,"scored":30},25,"mg",false,[16],[33],{"source":34,"section":35},"fda-sitagliptin","3",{"id":37,"form":24,"route":25,"label":38,"concentration":39,"markets":41,"refs":42},"tab-50","50 mg tablet",{"amount":40,"unit":29,"perUnit":24,"scored":30},50,[16],[43],{"source":34,"section":35},{"id":45,"form":24,"route":25,"label":46,"concentration":47,"markets":49,"refs":50},"tab-100","100 mg tablet",{"amount":48,"unit":29,"perUnit":24,"scored":30},100,[16],[51],{"source":34,"section":35},[53,76],{"id":54,"disease":55,"label":56,"population":59,"type":63,"unit":29,"dose":64,"refs":65,"notes":68},"adult","type-2-diabetes",{"fa":57,"en":58},"دیابت نوع ۲ — ۱۰۰ mg یک بار در روز","Type 2 diabetes — 100 mg once daily",{"minAge":60},{"value":61,"unit":62},18,"year","fixed",{"perDose":48,"dosesPerDay":5},[66],{"source":34,"section":67},"2.1",[69],{"text":70,"refs":73},{"fa":71,"en":72},"eGFR ۳۰ تا کمتر از ۴۵: ۵۰ mg؛ eGFR کمتر از ۳۰ یا دیالیز: ۲۵ mg یک بار در روز.","eGFR 30 to \u003C45: 50 mg; eGFR \u003C30 or dialysis: 25 mg once daily.",[74],{"source":34,"section":75},"2.2",{"id":77,"disease":55,"label":78,"population":81,"type":83,"unit":29,"dose":84,"refs":88},"peds",{"fa":79,"en":80},"زیر ۱۸ سال","Under 18 years",{"maxAge":82},{"value":61,"unit":62},"notCalculated",{"reason":85},{"fa":86,"en":87},"بی‌خطری و اثربخشی در کودکان ثابت نشده است.","Safety and effectiveness in children not established.",[89],{"source":34,"section":90},"8.4",[],[],[],[],[],{"status":97,"reviewer":98,"date":98},"unverified",null,[100],{"regimen":54,"formulation":45,"input":101,"expect":104},{"ageYears":102,"weightKg":103},55,80,{"perDose":48},[106],"A10BH01",{"status":108,"forms":109,"refs":122},"registered",[110,114,118],{"code":111,"en":112,"fa":113},"16303","SITAGLIPTIN 100MG TAB","قرص سیتاگلیپتین ۱۰۰ میلی‌گرم",{"code":115,"en":116,"fa":117},"22428","SITAGLIPTIN 50MG TAB","قرص سیتاگلیپتین ۵۰ میلی‌گرم",{"code":119,"en":120,"fa":121},"22429","SITAGLIPTIN 25MG TAB","قرص سیتاگلیپتین ۲۵ میلی‌گرم",[123],{"source":124,"section":125,"url":126},"darooyab-generic","G-4803\u002FSitagliptin","https:\u002F\u002Fwww.darooyab.ir\u002FG-4803\u002FSitagliptin",[128,132,136,139,142],{"kind":129,"url":130,"label":131},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=202425","ANDA202425",{"kind":133,"url":134,"label":135},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=983e9e14-e9bd-3136-e573-98b4dc67860b","FDA Sitagliptin",{"kind":137,"url":138,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa606023.html",{"kind":140,"url":141,"label":106},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BH01",{"kind":143,"url":126,"label":8},"darooyab",{"pregnancy":145,"lactation":154,"pediatric":162,"geriatric":169},{"level":146,"text":147,"quote":150,"refs":151},"caution",{"fa":148,"en":149},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary The limited available data with sitagliptin tablets in pregnant women are not sufficient to inform a drug- associated risk for major birth defects and miscarriage.",[152],{"source":34,"section":153},"8.1",{"level":146,"text":155,"quote":158,"refs":159},{"fa":156,"en":157},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of sitagliptin in human milk, the effects on the breastfed infant, or the effects on milk production.",[160],{"source":34,"section":161},"8.2",{"level":146,"text":163,"quote":166,"refs":167},{"fa":164,"en":165},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of sitagliptin have not been established in pediatric patients.",[168],{"source":34,"section":90},{"level":146,"text":170,"quote":173,"refs":174},{"fa":171,"en":172},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","… function should be assessed more frequently in elderly patients [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.3 )] .",[175],{"source":34,"section":176},"8.5",{"kind":178,"refs":179,"id":131},"ANDA",[180],{"source":34,"section":181},"SPL approval \u002F marketing category",1792444700461]